Related Experiment Video
Updated: May 4, 2026
Culture and Imaging of Ex Vivo Organotypic Pseudomyxoma Peritonei Tumor Slices from Resected Human Tumor Specimens
Published on: December 9, 2022
Clinicopathological features and prognosis of pseudomyxoma peritonei
Huan Wang1, Xuejun Wang2, Yanfang Ju1
1Department of Oncology, The General Hospital of PLA, Beijing 100853, P.R. China.
Abstract:
The aim of this study was to evaluate the effects of treatment and the factors influencing the postoperative recurrence and survival time for pseudomyxoma peritonei (PMP). A total of 39 patients with PMP who received treatment were analyzed in The General Hospital of PLA (Beijing, China) between 2002 and 2011. The patients received cytoreductive surgery (CRS) and 25 cases of PMP recurred. Seven patients received postoperative hyperthermic intraperitoneal chemoperfusion (HIPEC). The median follow-up was 40 months. There were eight mortalities in this period. The 5- and 10-year survival rates were 89.0 and 35.0%, respectively. The medians of overall survival (OS) and recurrence time were 37 and 4 months, respectively. Multivariate analyses revealed that pathological subtype was able to influence the recurrence (P=0.042) and OS (P=0.033) times, as an independent prognostic factor. HIPEC was significantly associated with postoperative recurrence time (P=0.017). Patients with disseminated peritoneal adenomucinosis had a more favorable prognosis. CRS combined with HIPEC was able to extend the postoperative recurrence time for patients with PMP.
Insights
Pseudomyxoma peritonei (PMP) treatments were evaluated, finding pathological subtype and hyperthermic intraperitoneal chemoperfusion (HIPEC) impact recurrence and survival. Combining cytoreductive surgery with HIPEC may extend recurrence-free survival for PMP patients.
Area of Science:
- Oncology
- Surgical Oncology
- Gastrointestinal Oncology
Background:
- Pseudomyxoma peritonei (PMP) is a rare malignancy with complex management.
- Understanding prognostic factors is crucial for optimizing patient outcomes.
Purpose of the Study:
- To assess treatment effects on PMP recurrence and survival.
- To identify independent prognostic factors influencing PMP patient outcomes.
Main Methods:
- Retrospective analysis of 39 PMP patients treated between 2002-2011.
- Evaluation of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC).
- Multivariate analysis to determine recurrence and overall survival (OS) predictors.
Main Results:
- The 5- and 10-year survival rates were 89.0% and 35.0%, respectively.
- Pathological subtype and HIPEC were significant factors influencing recurrence and OS.
- Disseminated peritoneal adenomucinosis indicated a better prognosis.
Conclusions:
- Pathological subtype is an independent prognostic factor for PMP recurrence and OS.
- HIPEC is associated with reduced postoperative recurrence.
- Combined CRS and HIPEC may improve recurrence-free survival in PMP patients.
More Related Videos
07:20Intraoperative Detection of Subtle Endometriosis: A Novel Paradigm for Detection and Treatment of Pelvic Pain Associated with the Loss of Peritoneal Integrity
Published on: December 21, 2012
07:54Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
